afib progression

I've been wondering.... in the absence of episodes, does afib still progress? I don't mean the absence of symptoms, as I know there's such a thing as "silent" afib, where the person isn't aware of episodes. (By "episode" I mean an irregular heartbeat that can be documented via ECG, whether perceived by the person or not.) I'm wondering if there are some sort of cellular (or electrical or structural or some other type?) changes that happen regardless of episodes, so it's silently progressing below the radar, so to speak. Google hasn't been much help on this one--I get AI responses like the one below, that define episodes in terms of perceived symptoms, and link to articles that do the same:

AI: Yes, atrial fibrillation (AFib) can still progress even if you are not experiencing any episodes, meaning the condition can worsen over time even if you aren't feeling symptoms;

Does anyone know? Thank you!

My personal experience, 20+ years in, is that progression does not have to happen (as I had a 2.5 month episode in my first 4 months of presenting with afib and most subsequent years my AF burden has been < 0.05%). However my experience is not common. However, atrial fibrosis can progress, though if you've previously had episodes typically you'd see more episodes with progression. In fact, it is this fibrosis progression that can happen after a successful ablation leading to more afib. Here is what Chat GPT4 has to say:

**Atrial fibrosis** is a pathological process characterized by excessive deposition of extracellular matrix proteins, primarily collagen, within the atrial myocardium. This structural remodeling is associated with impaired atrial function and an increased risk of atrial arrhythmias, particularly atrial fibrillation (AF). Understanding the progression of atrial fibrosis is crucial for identifying therapeutic targets and managing arrhythmias effectively.

---

### **Pathophysiology of Atrial Fibrosis**

1. **Triggers of Fibrosis**
- **Inflammation**: Chronic inflammation, often seen in conditions such as hypertension, diabetes, or myocarditis, activates fibroblasts.
- **Mechanical Stress**: Elevated atrial pressure from conditions like heart failure or mitral valve disease promotes fibroblast activation.
- **Neurohormonal Activation**: Activation of the renin-angiotensin-aldosterone system (RAAS) and adrenergic pathways contributes to fibrotic signaling.
- **Aging**: With age, increased oxidative stress and inflammatory markers contribute to fibrosis.

2. **Progression**
- **Initial Phase**: Activation of fibroblasts by profibrotic mediators such as transforming growth factor-beta (TGF-β).
- **Intermediate Phase**: Proliferation of myofibroblasts and increased production of collagen types I and III.
- **Advanced Fibrosis**: Dense collagen deposition disrupts electrical conduction and mechanical properties, predisposing the atrium to arrhythmias.

---

### **Stages of Atrial Fibrosis**

1. **Early Fibrosis**
- Often asymptomatic or associated with mild electrical remodeling.
- Minimal conduction abnormalities.

2. **Intermediate Fibrosis**
- Noticeable atrial conduction delays.
- Increased susceptibility to atrial arrhythmias, particularly paroxysmal AF.

3. **Advanced Fibrosis**
- Extensive scarring leads to persistent or permanent AF.
- Progressive loss of atrial contractile function (atrial cardiomyopathy).

---

### **Factors Contributing to Progression**

1. **Chronic Conditions**
- Hypertension, obesity, and diabetes accelerate atrial fibrosis.
- Chronic kidney disease and systemic inflammatory diseases also contribute.

2. **Atrial Fibrillation**
- Atrial fibrillation itself exacerbates fibrosis in a vicious cycle: AF promotes fibrosis, and fibrosis promotes AF (AF begets AF).

3. **Lifestyle Factors**
- Smoking, excessive alcohol consumption, and physical inactivity contribute to fibrosis progression.

---

### **Clinical Implications**

1. **Electrophysiological Consequences**
- Fibrosis disrupts normal atrial conduction, creating areas of slowed conduction and reentry circuits, increasing the risk of arrhythmias.

2. **Impact on AF Treatment**
- Advanced fibrosis reduces the success rate of interventions like catheter ablation.
- Extensive fibrosis detected by imaging (e.g., late gadolinium enhancement MRI) is a predictor of AF recurrence.

---

### **Management and Potential Therapies**

1. **Risk Factor Modification**
- Aggressive control of hypertension, diabetes, and obesity can slow fibrosis progression.

2. **Pharmacological Therapies**
- **RAAS Inhibitors**: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce fibrosis by inhibiting profibrotic pathways.
- **Aldosterone Antagonists**: Spironolactone and eplerenone mitigate aldosterone-induced fibrosis.
- **Antioxidants**: Target oxidative stress, though clinical benefits remain uncertain.

3. **Emerging Therapies**
- Antifibrotic agents targeting TGF-β signaling or fibroblast activity are under investigation.
- Stem cell therapy and matrix metalloproteinase inhibitors show potential but require further study.

---

### **Prognosis**
The progression of atrial fibrosis is closely linked to atrial dysfunction, arrhythmia burden, and adverse cardiovascular outcomes. Early detection and intervention are critical to slowing progression and improving patient outcomes.

**References**:
- Jalife J, Kaur K. "Atrial remodeling and fibrosis in atrial fibrillation." *Journal of Cardiovascular Electrophysiology*. 2015.
- Nattel S, Harada M. "Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives." *Journal of the American College of Cardiology*. 2014.

George, thank you very much for the detailed response! My very simplified takeaway: Yes, afib can progress without "episodes," through atrial fibrosis. But you may be able to slow/limit fibrosis by managing things like inflammation, hypertension, diabetes, obesity, alcohol consumption, and smoking. I had not heard of the pharmacological therapies mentioned above being prescribed for people with afib--I've only hear about various antiarrhythmic drugs--but I am relatively new to this. Interesting.

How is atrial fibrosis clinically diagnosed and clinically staged. Can this be asked for as part of regular.cardiac evaluations? May have missed this in the above explanation.

Quote
Mark
How is atrial fibrosis clinically diagnosed and clinically staged. Can this be asked for as part of regular.cardiac evaluations?.

Here is another Chat GPT 4 answer below. I'll have to say, unless it was extremely necessary, I would not let anybody use gadolinium as an MRI contrast agent. I'm the healthcare power of attorney for a family member who has had many MRI's with gad. After investigating it, there aren't many studies, but a heck of a lot of anecdotes that gad can really mess up some people. In some cases people have gone to great lengths to get gad out of the body with a variety of detox methods and seen their symptoms resolve or at least improve. Gadolinium is a heavy metal. I have a doc who would measure serum Galectin-3. Not for my afib, but as a marker he thought he could improve with lifestyle & supplements, He's a cardiologist & cardiothoracic surgeon, but I was consulting with him for maximizing health span.

**Atrial fibrosis** is diagnosed using a combination of imaging techniques, biomarkers, and clinical evaluations. Since atrial fibrosis affects the structure and function of the heart, it is often detected indirectly through its impact on atrial electrical activity or through specialized imaging technologies. Here’s a breakdown of the diagnostic methods:

---

### **1. Imaging Techniques**

#### **a. Cardiac Magnetic Resonance Imaging (MRI)**
- **Late Gadolinium Enhancement (LGE-MRI):**
- LGE-MRI is the gold standard for noninvasive detection of atrial fibrosis.
- Gadolinium contrast highlights areas of fibrotic tissue as bright regions on the scan.
- Particularly useful in evaluating the extent of fibrosis in atrial fibrillation patients.
- **Clinical Relevance**: Extent of fibrosis is often categorized using the Utah classification (Stages 1–4) and correlates with arrhythmia burden and outcomes of catheter ablation.
- **Reference**: McGann C, Akoum N, Patel A, et al. "Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI." *Circulation*. 2011.

#### **b. Echocardiography**
- **Speckle Tracking Echocardiography:**
- Measures atrial strain and strain rate, which are indicators of atrial stiffness caused by fibrosis.
- Reduced atrial strain suggests underlying fibrosis.
- **Reference**: Cameli M, Lisi M, Focardi M, et al. "Left atrial deformation analysis by speckle tracking echocardiography for prediction of cardiovascular outcomes." *American Journal of Cardiology*. 2012.

- **3D Echocardiography:**
- Provides volumetric data to assess atrial size and function, which are indirectly affected by fibrosis.

---

### **2. Electroanatomical Mapping**
- Used during catheter ablation procedures to map atrial electrical activity.
- Areas of fibrosis are identified as regions with low-voltage signals or conduction block.
- **Reference**: Verma A, Wazni OM, Marrouche NF, et al. "Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation." *Circulation*. 2005.

---

### **3. Biomarkers**
- **Collagen Turnover Markers**:
- Serum biomarkers like **procollagen type I carboxy-terminal peptide (PICP)** and **procollagen type III N-terminal peptide (PIIINP)** reflect extracellular matrix remodeling and are indicative of fibrosis.
- Elevated levels suggest increased fibrotic activity in the myocardium.
- **Reference**: Russo C, Jin Z, Homma S, et al. "Left atrial passive emptying function and left atrial fibrosis." *JACC: Cardiovascular Imaging*. 2014.

- **Galectin-3:**
- A biomarker associated with myocardial fibrosis and inflammation.
- Elevated in patients with atrial fibrillation and heart failure.
- **Reference**: de Boer RA, van Veldhuisen DJ, et al. "Galectin-3: a novel mediator of heart failure development and progression." *European Journal of Heart Failure*. 2009.

---

### **4. Electrocardiogram (ECG)**
- **P-wave Characteristics**:
- Prolonged P-wave duration or dispersion suggests atrial remodeling, which may be linked to fibrosis.
- While not specific, changes in P-wave morphology can prompt further investigation.

---

### **5. Histological Analysis**
- **Endomyocardial Biopsy:**
- Provides a direct evaluation of atrial tissue for fibrosis but is rarely performed due to its invasive nature.
- Typically reserved for cases requiring histological confirmation of suspected cardiac amyloidosis or myocarditis.

---

### **6. Clinical Context**
- Diagnosis of atrial fibrosis often correlates with clinical risk factors and conditions, such as:
- Atrial fibrillation
- Hypertension
- Heart failure
- Obesity or metabolic syndrome

---

### **Summary**
- **Imaging (LGE-MRI)** and **echocardiography** are the most reliable noninvasive methods for diagnosing atrial fibrosis.
- Biomarkers like **PICP**, **PIIINP**, and **galectin-3** provide insights into fibrotic activity.
- Electroanatomical mapping and histological analysis offer more direct but less commonly used diagnostic approaches.

**Early detection of atrial fibrosis** is essential for managing associated conditions like atrial fibrillation and tailoring therapeutic interventions.

---

**References**:
- McGann C, Akoum N, Patel A, et al. "Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI." *Circulation*. 2011.
- Russo C, Jin Z, Homma S, et al. "Left atrial passive emptying function and left atrial fibrosis." *JACC: Cardiovascular Imaging*. 2014.
- Verma A, Wazni OM, Marrouche NF, et al. "Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation." *Circulation*. 2005.

Good luck Nancy! You answered what you should do to improve your chances of slowing down progression.

My AF was for almost 4 months permanent in 2015. Cardiologist and EP gave me nocebos but i decided to listen to other advise.
Have so far been almost AF free but take Flecainide as PIP, kept my BMI at about 22 but i'm fitter now than i was in 2015 (74 y/o now)

Another doctor's take on progression:
[www.youtube.com]